Wikipedia:Articles for deletion/Novelos Therapeutics


 * The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review).  No further edits should be made to this page.

The result was   delete. Secret account 13:52, 10 December 2009 (UTC)

Novelos Therapeutics

 * – (View AfD) (View log · AfD statistics)

Declined speedy (I have no idea why, many companies have rights to pharma compounds, but that doesn't make them "important or significant"). Most of the Ghits I come up with are directory-type listings or regurgitation of company press releases, not amounting to the significant coverage required by WP:N and WP:CORP. NB article was created by editor with WP:COI, now blocked for spamming. ukexpat (talk) 21:41, 3 December 2009 (UTC)
 * Delete per nom. No evidence of notability.  WP:SOAP  7  22:52, 3 December 2009 (UTC)
 * Delete - I understood declining the speedy, A7 isn't about an article being notable, but asserting that it's notable. The article does so, if weakly. But it certainly falls short of actually being notable; I made a real effort to find sources, but I can't find anything but press releases. I suppose that it's worth mentioning that the article is part of a coordinated effort to promote this company on the web, per WP:COIN. --  At am a  頭 23:03, 3 December 2009 (UTC)
 * Delete - I can find only press releases. -- Whpq (talk) 11:10, 4 December 2009 (UTC)
 * Delete Appears to be a lot of Google hits (some of which are promotional attempts) but no evidence of notability per WP:CORP. Johnuniq (talk) 01:42, 5 December 2009 (UTC)
 * Delete per WP:CRYSTAL - their drugs are still in trials. Bearian (talk) 17:01, 5 December 2009 (UTC)
 * Delete: I can't find significant coverage for this company. Joe Chill (talk) 17:09, 6 December 2009 (UTC)
 * Do not Delete according to the National Cancer Institute:
 * NOV-002 is manufactured by Novelos Therapeutics
 * A stabilized formulation of disodium glutathione disulfide (GSSG; oxidized glutathione) and cisplatin (1000:1) with potential chemoprotective and immunomodulating activities. Mimicking endogenous GSSG, glutathione disulfide NOV-002 acts as a competitive substrate for gamma-glutamyl-transpeptidase (GGT), which may result in the S-glutathionylation of proteins, predominantly actin, a redox stress on endoplasmic reticulum (ER), and ER stress-induced apoptosis; S-glutathionylation may be stimulated by reactive oxygen species (ROS) liberated by a glutathione disulfide NOV-002-induced increase in GGT activity. Glutathione disulfide NOV-002 may also induce phosphorylation of proteins such as ERK and p38, two kinases that play critical regulatory roles in cell proliferation and apoptosis. The cisplatin component of this agent does not provide an effective therapeutic concentration of cisplatin in vivo. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
 * Synonym: oxidized glutathione NOV-002
 * Foreign brand name: Glutoxim
 * Code name: NOV-002
 * source: http://www.cancer.gov/drugdictionary/?CdrID=494994 —Preceding unsigned comment added by 4.238.245.42 (talk) 03:48, 9 December 2009 (UTC) (Note: — 4.238.245.42 (talk • contribs) has made few or no other edits outside this topic.  )
 * Er...so? Plenty of companies make products but that doesn't mean they fulfill Wikipedia's notability requirements. – ukexpat (talk) 03:56, 9 December 2009 (UTC)


 * Do not Delete
 * Dr John Bell et al,
 * To be eligible in meeting wikipedia standards in addition to being part of the National Cancer Institute reference. NOV-002 manufactured by Novelos is making the Media and that substantiates a second criteria for Wikipedia listing:


 * Vernay Mills of Miami Florida her breast cancer was cured made the Channel 7 FOX news story on Television.


 * Medical Reports: Targets Tumors
 * http://www.wsvn.com/features/articles/medicalreports/MI137669/ —Preceding unsigned comment added by 4.238.241.68 (talk) 16:27, 9 December 2009 (UTC) (Note: — 4.238.241.68 (talk • contribs) has made few or no other edits outside this topic.  )


 * Delete - can't find anything that merits notability under WP:CORP. Lots of promotional stuff, but not enough reliable, third-party stuff to merit inclusion, in my opinion.  As a side note, it's probably a conflict of interest (doesn't really matter though, since I don't think it's notable enough to warrant inclusion).   Cocytus   [»talk«]  22:37, 9 December 2009 (UTC)


 * Do Not Delete Fulfills three Wikipedia notability requirements:
 * 1. Company manufactures certain medications that might be a breakthrough in cures for certain types of cancer.
 * 2. Media has noticed.
 * 3. Their lead medication is in the National Cancer Institute dot Gov Dictionary. — Preceding unsigned comment added by 4.238.245.77 (talk • contribs) (Note: — 4.238.245.77 (talk • contribs) has made few or no other edits outside this topic.  )
 * Comment: You may wish to re-read WP:N or WP:ORG.  7  03:35, 10 December 2009 (UTC)

Note: Three 4.238.24x.xxx SPA accounts are geographically located near the address of the company that is the subject of this article. 7 03:35, 10 December 2009 (UTC)


 * Comment - in response to the IP's last statements, point 1 runs afoul of WP:CRYSTAL, since (as you state) it might be a breakthrough, point 2 is subjective, and in my opinion (and the opinions of others, as based on this AfD) the threshold for notability has not been met. I really do hope these drugs ending being a major breakthrough in cancer treatment, that would be great, but the point here is to discuss the merits of the article, and under our current policies, I feel I have no choice but to vote delete.   Cocytus   [»talk«]  04:58, 10 December 2009 (UTC)


 * The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.